At the time of writing, Denali Therapeutics Inc [DNLI] stock is trading at $25.16, up 0.16%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DNLI shares have gain 0.76% over the last week, with a monthly amount glided 16.27%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Denali Therapeutics Inc [NASDAQ: DNLI] stock has seen the most recent analyst activity on December 13, 2023, when Citigroup initiated its Buy rating and assigned the stock a price target of $32. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $38 on September 06, 2023. SVB Securities initiated its recommendation with a Outperform and recommended $50 as its price target on January 30, 2023. In a note dated November 02, 2022, BTIG Research upgraded an Buy rating on this stock but restated the target price of $38.
For the past year, the stock price of Denali Therapeutics Inc fluctuated between $14.56 and $25.90. Currently, Wall Street analysts expect the stock to reach $40 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $25.16 at the most recent close of the market. An investor can expect a potential return of 58.98% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
According to Denali Therapeutics Inc [NASDAQ:DNLI], the company’s sales were 1.27M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 1.03% with Operating Profit Margin at 1.63%, Pretax Profit Margin comes in at 1.38%, and Net Profit Margin reading is 1.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.34 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.62 points at the first support level, and at 24.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.70, and for the 2nd resistance point, it is at 26.23.
Ratios To Look Out For
It is important to note that Denali Therapeutics Inc [NASDAQ:DNLI] has a current ratio of 12.46. In addition, the Quick Ratio stands at 12.46 and the Cash Ratio stands at 1.0. Considering the valuation of this stock, the price to sales ratio is 2836.15, the price to book ratio is 2.60.
Transactions by insiders
Recent insider trading involved SATO VICKI L, Director, that happened on Sep 03 ’24 when 3080.0 shares were sold. President and CEO, Watts Ryan J. completed a deal on Aug 20 ’24 to sell 2260.0 shares. Meanwhile, Director Krognes Steve E. sold 1727.0 shares on Aug 20 ’24.
